As you may be aware Cogentum’s client Acrux (ASX:ACR) yesterday announced that the FDA has approved its Axiron product for marketing in the US. The news received wide media coverage which is a great reflection of the importance of the news!
This announcement is a watershed moment for the Australian Biotech sector and marks a significant [...]

[Read more →]

Cogentum client Acrux today announced one of the biggest licensing  deals in Australian Biotech history. The deal with Eli Lilly ranks up there as one of the biggest outcomes for an Australian biotech. From the announcements you will see that this is a superb result for any Australian company seeking to license it’s technology.

Cogentum worked [...]

[Read more →]

Great news is continuing to emerge from the Australian biotech sctor.
We are glad to see that one of our clients, Acrux, is leading the charge as it continues to build a cogent story for its investors and the market.
Equally pleasing is the rapid progress of Universal Biosensors (sadly, not a client!). This company is, in our [...]

[Read more →]

The following piece appeared in September 28th edition of Bioshares #330, Australia’s leading analysis and commentary on the Biotech sector. It summarises our out take on the 2009 Bioshares conference held at Thredbo in September.

Don’t worry about your Technology, show me the Strategy

The 2009 Thredbo summit graphically illustrated why strategy is becoming increasingly more valuable [...]

[Read more →]